In this slide show we highlight some of the top news on lung cancer in 2016, including an immunotherapy approval from the FDA, and studies on depression in lung cancer patients, serious side effects to watch for when using immunotherapies, and more.
Surufatinib/Toripalimab Shows Encouraging Activity in NSCLC and SCLC
Surufatinib/toripalimab elicited an ORR of 57.1% in patients with treatment-naïve NSCLC and 15.8% in patients with pretreated SCLC in a phase 2 trial.
Exploring the Value of Preoperative CAPTEM in Atypical Lung NETs
Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.
AI, Immunotherapy, More Key Lung Cancer Advances Highlighted at 2025 ELCC
An expert panel at ELCC 2025 reviews the MARIPOSA trial's implications for first-line therapy in EGFR-mutated NSCLC and broader advancements.
Achieving Health Equity in Lung Cancer Surgery
Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.
Continuous Second-Line Immunotherapy May Benefit Pretreated Lung Cancer
Patients with driver gene–negative non–small cell lung cancer who received immunotherapy beyond progression experienced better survival outcomes.
AI/ML-Based Software Improves Diagnostic Accuracy in Lung Cancer
The diagnostic accuracy of radiologists aided by the eyonis LCS AI software was greatly improved compared with when radiologists were unaided.